Olivier Leupin

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. pmc Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function
    Olivier Leupin
    Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    J Biol Chem 286:19489-500. 2011
  2. doi request reprint Does osteocytic SOST suppression mediate PTH bone anabolism?
    Ina Kramer
    Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Trends Endocrinol Metab 21:237-44. 2010
  3. pmc Control of the SOST bone enhancer by PTH using MEF2 transcription factors
    Olivier Leupin
    Bone and Cartilage Unit, Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
    J Bone Miner Res 22:1957-67. 2007

Detail Information

Publications3

  1. pmc Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function
    Olivier Leupin
    Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
    J Biol Chem 286:19489-500. 2011
    ..Together these data indicate that the interaction of sclerostin with LRP4 is required to mediate the inhibitory function of sclerostin on bone formation, thus identifying a novel role for LRP4 in bone...
  2. doi request reprint Does osteocytic SOST suppression mediate PTH bone anabolism?
    Ina Kramer
    Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Trends Endocrinol Metab 21:237-44. 2010
    ....
  3. pmc Control of the SOST bone enhancer by PTH using MEF2 transcription factors
    Olivier Leupin
    Bone and Cartilage Unit, Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
    J Bone Miner Res 22:1957-67. 2007
    ..Expression of the osteocyte-derived bone formation inhibitor sclerostin in adult bone requires a distant enhancer. We show that MEF2 transcription factors control this enhancer and mediate inhibition of sclerostin expression by PTH...